Eli Lilly statement to NBC 7

Patient safety is Lilly's top priority, and we actively engage in monitoring, evaluating, and reporting safety information for all our medicines.

The FDA-approved label for Zepbound warns that Zepbound may be associated with gastrointestinal adverse reactions, sometimes severe.

Zepbound's label also warns that suicidal behavior and ideation have been reported in clinical trials with other chronic weight management products. It further states that Zepbound should be avoided in patients with a history of suicidal attempts or active suicidal ideation. Patients treated with Zepbound should be monitored for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior. Zepbound should be discontinued in patients who experience suicidal thoughts or behaviors.

It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound's label contains a boxed warning regarding potential risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2.

If someone is experiencing any side effects while taking any Lilly medication we encourage them to speak with their healthcare provider.

Lilly is deeply concerned about the proliferation of counterfeit, fake, and other unapproved and untested incretin knockoffs. Poison control centers, regulators, and patient advocacy groups have issued warnings about the unique health risks posed by compounding incretins, and the Australian government announced a complete ban on compounded incretins due to patient safety concerns.

According to FDA, "compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness. Therefore, compounded drugs should only be used to meet a patient's needs if the patient's medical needs cannot be met by an available FDA-approved drug." Because all doses of Lilly's FDA-approved Mounjaro and Zepbound medications are available, patients should not be exposed to the higher risks posed by unapproved knockoffs.

Lilly is committed to making life better for people living with diabetes and obesity through developing medicines that change the way healthcare providers can treat these diseases. The development and approvals of Mounjaro and Zepbound reflect our commitment to that mission. Our advertising reinforces that obesity is a serious health condition and discourages off-label use for cosmetic weight loss. Shame – imposed by others on people with obesity through misconceptions and stigma – has no place in the conversation.